What's new

Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 22, Status: Authorised

Jun 17, 2025 - 15:05
 0
Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 22, Status: Authorised
Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 22, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Arexvy, recombinant re...

Next Article

Human medicines European public assessment report (EPAR): Lumeblue (previously M...

Related Posts

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 10, 2025  0

Orphan designation: S-[5-(omega-methoxypoly(oxyethylene)-2-oxopentyl)]-L-cysteinylglycyl-L-serinylglycylgylcyl-L-isoleucyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-histyl-L-isoleucyl-L-valyl-L-glutaminyl-L-serinyl-L-isoleucyl-L-isoleucyl-L-asparaginyl-L-threonyl-L-serinamide, acetate salt Treatment of cutaneous T-cell lymphoma, 13/04/2021 Withdrawn

Orphan designation: S-[5-(omega-methoxypoly(oxyethylene...

Jun 10, 2025  0

EMEA-003170-PIP01-21-M02

EMEA-003170-PIP01-21-M02

May 14, 2025  0